Source: Eur Respir J 2014; 44: 1289-1295
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Yoo Jung-Wan, Jo Kyung-Wook, Kang Bo-Hyung, Kim Mi Young, Yoo Bin, Lee Chang-Keun, Kim Yong-Gil, Yang Suk-Kyun, Byeon Jeong-Sik, Kim Kyung-Jo, Ye Byong Duk, Shim Tae Sun. Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy. Eur Respir J 2014; 44: 1289-1295

Member's Comments

No comment yet.

Related content which might interest you: Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Tuberculosis and tumor necrosis factor alpha antagonist: Our experience Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008 Tumor necrosis factor α in chronic pulmonary diseases of children Source: Eur Respir J 2002; 20: Suppl. 38, 193s Year: 2002 The levels of tumour necrosis factor-alpha and interleukin-1 in newly diagnosed and multi drug resistant tuberculosis Source: Annual Congress 2004 - Clinical and diagnostic features of tuberculosis Year: 2004 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007